Eloxx Pharmaceuticals (ELOX) Financials

Eloxx Pharmaceuticals’ Q1 2026 statements show a company that remains pre-revenue and dependent on external financing. Revenue was $0, while the company reported a net loss of $3.8 million, or $0.08 per share. The loss was substantially worse than the $1.7 million loss reported in Q1 2025, although the per-share loss improved because the weighted-average share count increased sharply.

Cash increased to $6.4 million at March 31, 2026, from $4.8 million at September 30, 2023. However, the improvement was primarily financing-driven: Eloxx raised $7.0 million through common equity during Q1 2026, while operating activities consumed $5.5 million. At the latest quarterly burn rate, cash alone would provide only a limited runway without additional financing or a meaningful reduction in expenses.

• Liquidity improved year over year. Cash and equivalents rose to $6.4 million in Q1 2026 from $4.8 million in Q3 2023, and total current assets increased to $8.5 million from $5.6 million.
• Liabilities declined substantially. Total liabilities fell to $16.1 million from $26.1 million in Q3 2023, while short-term and long-term debt were both reported at zero in Q1 2026.
• Equity financing provided a near-term cash benefit. The $7.0 million common-stock issuance more than offset the company’s operating cash burn and produced a $1.6 million net increase in cash during the quarter.
• Investing requirements remain minimal. Eloxx reported no investing cash outflow in Q1 2026 and had no net property, plant and equipment, suggesting limited near-term capital-expenditure needs.
• Operating liabilities remain elevated despite the overall decline. Accounts payable and accrued expenses totaled approximately $4.0 million, while other current liabilities were $11.8 million. The composition and payment timing of these obligations will be important to monitor.
• Research and development spending indicates continued development activity. R&D expense was $1.7 million in Q1 2026, up from $510,000 in Q1 2025, but the available statements do not establish whether this higher spending is producing clinical or commercial progress.
• The company has not generated revenue. Total revenue was $0 in both Q1 2026 and Q1 2025, leaving Eloxx without operating sales to fund its research and administrative expenses.
• Operating cash burn deteriorated sharply. Cash used in operating activities increased to $5.5 million in Q1 2026 from operating cash inflow of $1.2 million in Q1 2025 and cash outflows of $2.0 million in Q4 2023 and $3.5 million in Q3 2023.
• Operating expenses rose significantly. SG&A increased to $2.1 million from $712,000 year over year, while total operating expenses increased to $3.8 million from $1.2 million. This drove an operating loss of $3.8 million despite the absence of revenue.
• Shareholder dilution is a major risk. Weighted-average basic shares outstanding increased to 48.2 million in Q1 2026 from 3.8 million in Q1 2025 and 2.6 million in Q4 2023. Future financing needs could further dilute existing shareholders.

Overall, the balance sheet is less burdened by debt and has more cash than in late 2023, but the improvement is heavily reliant on equity issuance. The combination of zero revenue, accelerating operating expenses, a $5.5 million quarterly cash burn and negative total equity of $7.6 million leaves Eloxx financially fragile. Investors should focus on additional financing, expense reductions, clinical milestones and any evidence that the company can eventually generate commercial revenue.